July 8 (Reuters) - Hikma Pharmaceuticals Plc said itexpects revenue to rise 17 percent in 2013, up from its previousforecast of 13 percent, boosted by strong sales of its genericantibiotic doxycycline.
The company said it expected full-year revenue of about 200million pounds ($297.65 million) and operating margins of morethan 30 percent in its generic business.